Feds to reimburse states for Part D

Researchers addressed the current trends in prescription drug use and spending among Medicare Advantage beneficiaries during the first year of clinician access to a real-time prescription benefit tool.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

Researchers investigated the timing of hypertension diagnosis, exploring how it’s associated with medication prescribing and long-term cardiovascular outcomes.

With federal reform continuing to stall, Drug Topics caught up with Iowa State Representative Brett Barker, PharmD, to discuss how his state is regulating pharmacy benefit managers.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses how diabetes advancements like GLP-1s and CGM have impacted the management of insulin.

Researchers assessed the difference between hidradenitis suppurativa and other skin conditions regarding the initiating events, inflammatory signature, and molecular and clinical features of each disease.